TORONTO, Oct. 1 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that Philippe Couillard, MD, former Minister of Health and Social Services for Quebec, has been appointed to its Board of Directors.
Dr. Couillard began his career as a neurosurgeon in 1985 and served as the chief of the department of Neurosurgery at St. Luc Hospital from 1989 to 1992. From 1992 to 1996, he co-founded and ran the department of Neurosurgery in Dhahran in Saudi Arabia. On his return to Canada in 1996, Dr. Couillard became a professor in the Faculty of Medicine at the University of Sherbrooke and was both the director and chief surgeon of the department of Surgery at the Centre Hospitalier Universitaire de Sherbrooke until 2003. He was elected to the Quebec National Assembly and served as Minister of Health and Social Services of Quebec from 2003 to 2008 - making him the longest serving health minister in that province since 1958. During his term in office, Dr. Couillard directed a number of major reforms of the Quebec healthcare system and established a bi-annual Quebec-France symposium on health. Dr. Couillard is currently a senior fellow in health law at McGill University and a partner with Persistence Capital Partners, a Montreal-based private equity fund dedicated to the healthcare sector.
Graham Strachan, Chairman of the Amorfix Board of Directors, commented, "We are delighted to have Dr. Couillard join the Company's Board. Philippe's great clinical and scientific accomplishments, combined with his senior political experience, will be a tremendous asset to Amorfix as we work toward bringing our treatments and diagnostics for brain wasting diseases successfully to market."
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, variant Creutzfeldt-Jakob Disease (vCJD) and Cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. ProMIS(TM) is an "in silico" rational selection approach that can be applied to any protein where the normal folding structure is at least partially known. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and Cancer. The Company's diagnostic programs include a blood screening test for diagnosis of vCJD and an ultrasensitive method for the detection of aggregated ss-Amyloid in brain tissue of animal models of Alzheimer's disease, months prior to plaque formation.
This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Amorfix Life Sciences Ltd.
For further information: For further information: Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899, email@example.com; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, firstname.lastname@example.org